Drug Profile
Research programme: bispecific antibody therapeutics - Amgen/Bayer
Alternative Names: CD33 BiTE antibody; EGFR BiTE antibody; HER2 BiTE antibody; MCSP BiTE antibodyLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 29 Mar 2019 Preclinical development is ongoing in Germany
- 29 Mar 2019 Pharmacodynamics and pharmacokinetics data from a preclinical study in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)